Rx Times Pharmacy Magazine

Pharmacy News

• Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial
  June 19, 2013 BRIDGEWATER, N.J.–(BUSINESS WIRE)–Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC QB: SNTI) reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T. In cohort 2, the requisite number of 3 patients was evaluable for the primary safety endpoint from the total of 4 enro
  
  
• Research and Markets: Global Muscular Atrophy Pipeline Capsule – 2013
  June 19, 2013 DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/m7tl69/global_muscular) has announced the addition of the "Global Muscular Atrophy Pipeline Capsule – 2013" report to their offering. Fore Pharma's latest report Global Muscular Atrophy Pipeline
  
  
• Research and Markets: Influenza B Infections – Pipeline Review, H1 2013
  June 19, 2013 DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/jj399r/influenza_b) has announced the addition of the "Influenza B Infections – Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Influenza B Infections – Pipelin
  
  
• Impact Analytical Opens New State-of-the-Art Laboratory Facility
  June 19, 2013 MIDLAND, Mich.–(BUSINESS WIRE)–Impact Analytical has begun operations in a new 17,000-square-foot facility.
  
  
• Iroko Pharmaceuticals Inc. Files Registration Statement for Initial Public Offering
  June 19, 2013 PHILADELPHIA–(BUSINESS WIRE)–Iroko Pharmaceuticals Inc. (www.iroko.com), announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its ordinary shares. All ordinary shares proposed to be offered for sale will be
  
  
• Research and Markets: Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors Report
  June 19, 2013 DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/ff59xb/triple_analysis) has announced the addition of the "Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors" report to their offering. This triple analysis focuses on cance